We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

The Medicines Patent Pool Initiative, set up with the aim of persuading pharmaceutical companies to waive intellectual property rights to their HIV/AIDS drugs, has announced its first possible successes.

Set up by Unitaid in 2009, the pool has announced that it is in negotiations with F. Hoffman-La Roche, Gilead Sciences, Sequoia Pharmaceuticals and ViiV Healthcare (a joint venture of GlaxoSmithKline (GSK) and Pfizer).

The biggest surprise is the discussions with ViiV Healthcare, said Sarah Boseley in her Guardian blog, as GSK had seemed uninterested in the concept. Although committed to improving access to its medicines in poor countries, chief executive Andrew Witty said they were taking other routes.

The patent pool has listed on its website all the companies it has approached, along with the replies from those who are "less than enthusiastic", said the article.

Link to full article in The Guardian